Loading
Latest filing published 08 Apr 2025 for Humacyte, Inc., €18k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Michael T. Constantino (senior executive) discloses dealings in 2 companies, chiefly Humacyte, Inc. and 9 Meters Biopharma, Inc. Over a trading history stretching from 20 August 2020 to 7 April 2025, the count stands at 12 filings.
Every open-market trade on record is a purchase: 11 purchases worth €170k, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 1 share grant. Since January 2025: 1 purchase and no sales on the market.
The median purchase comes to €18k. 6 out of 9 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
On 8 April 2025 came the latest disclosure, an open-market purchase for €18k in Humacyte, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations